On July 21, 2026, BioLife Solutions, Inc. entered into a definitive merger agreement to be acquired by Repligen Corporation for a total enterprise value of approximately $1.5 billion. BioLife stockholders will receive $11.25 in cash and 0.1442 shares of Repligen common stock per share, representing a total value of $31.00 per share. The transaction is expected to close in the fourth quarter of 2026, subject to stockholder approval and regulatory clearances. Additionally, BioLife reported preliminary unaudited second quarter 2026 revenue of $28.5 million, a 21% increase year-over-year. The company operates in the life sciences industry, developing and supplying cell processing tools and biopreservation media for the cell and gene therapy market.